Literature DB >> 25519867

Severe drug-induced interstitial lung disease successfully treated with corticosteroid plus recombinant human soluble thrombomodulin.

Satoshi Marumo1, Masahiro Shirata1, Minoru Sakuramoto1, Motonari Fukui1.   

Abstract

There is no established therapeutic option for corticosteroid (CS) refractory drug-induced interstitial lung disease (DILD). We report a case of CS refractory severe DILD successfully treated with recombinant human soluble thrombomodulin (rhTM). A 64-year-old Japanese man was admitted with symptoms of fever, dry cough and dyspnoea. A chest radiograph showed bilateral infiltrations. DILD from Nijutsutou, a Chinese medicine, was suspected based on a history of similar interstitial lung disease after its administration 4 years prior and a positive drug-induced lymphocyte stimulation test. Nijutsutou was promptly discontinued and high doses of CS administered, but the patient's bilateral infiltrations remained unimproved. Since coagulation tests also indicated a rapid aggravation of coagulopathy, rhTM was added to the CS therapy. The patient's lung infiltration ameliorated and plasma levels of D-dimer and high morbidity group box 1 (HMGB1) decreased. rhTM may be an alternative agent for CS refractory DILD. Further study is necessary to confirm this. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25519867      PMCID: PMC4275748          DOI: 10.1136/bcr-2014-207996

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  The acute respiratory distress syndrome.

Authors:  L B Ware; M A Matthay
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

Review 2.  Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

Authors:  S Imokawa; T V Colby; K O Leslie; R A Helmers
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

3.  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.

Authors:  H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki
Journal:  J Thromb Haemost       Date:  2006-10-13       Impact factor: 5.824

4.  Interstitial lung disease associated with gefitinib.

Authors:  Kensuke Kataoka; Hiroyuki Taniguchi; Yoshinori Hasegawa; Yasuhiro Kondoh; Tomoki Kimura; Osamu Nishiyama; Kazuyoshi Imaizumi; Tsutomu Kawabe; Hiroaki Kume; Kaoru Shimokata
Journal:  Respir Med       Date:  2005-08-30       Impact factor: 3.415

5.  Anticoagulant therapy for idiopathic pulmonary fibrosis.

Authors:  Hiroshi Kubo; Katsutoshi Nakayama; Masaru Yanai; Tomoko Suzuki; Mutsuo Yamaya; Mika Watanabe; Hidetada Sasaki
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Drug-induced lung disease: high-resolution CT and histological findings.

Authors:  Joanne R Cleverley; Nicholas J Screaton; Melanie P Hiorns; Julia D A Flint; Nestor L Müller
Journal:  Clin Radiol       Date:  2002-04       Impact factor: 2.350

7.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

8.  Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study.

Authors:  Kenji Tsushima; Koichi Yamaguchi; Yuta Kono; Toshiki Yokoyama; Keishi Kubo; Takuma Matsumura; Yasunori Ichimura; Mitsuhiro Abe; Jiro Terada; Koichiro Tatsumi
Journal:  Pulm Pharmacol Ther       Date:  2014-05-14       Impact factor: 3.410

Review 9.  The role of thrombomodulin lectin-like domain in inflammation.

Authors:  Yi-Heng Li; Cheng-Hsiang Kuo; Guey-Yueh Shi; Hua-Lin Wu
Journal:  J Biomed Sci       Date:  2012-03-27       Impact factor: 8.410

10.  Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome.

Authors:  D Kudo; M Toyama; T Aoyagi; Y Akahori; H Yamamoto; K Ishii; E Kanno; R Maruyama; M Kaku; S Kushimoto; K Kawakami
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more
  2 in total

1.  Sequential adjuvant chemoradiotherapy-induced diffuse alveolar haemorrhage in a patient with breast cancer successfully treated with corticosteroid plus recombinant human soluble thrombomodulin.

Authors:  Takamasa Kitajima; Satoshi Marumo; Yurina Maeshima; Motonari Fukui
Journal:  BMJ Case Rep       Date:  2016-10-28

2.  Anti-inflammatory effect of recombinant thrombomodulin for fulminant hepatic failure.

Authors:  Kazutaka Kurokohchi; Osamu Imataki; Fumiyoshi Kubo
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.